The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer

Yu, SL; Hsiao, YJ; Cooper, WA; Choi, YL; Aviles-Salas, A; Chou, TY; Coudry, R; Raskin, GA; Fox, SB; Huang, CC; Jeon, YK; Ko, YH; Ku, WH; Kwon, GY; Leslie, C; Lin, MC; Lou, PJ; Scapulatempo-Neto, C; Mendoza Ramirez, S; Savelov, N; Shim, HS; Lara Torres, CO; Cunha, IW; Zavalishina, L; Chen, YM

Author(s): Yu, SL; Hsiao, YJ; Cooper, WA; Choi, YL; Aviles-Salas, A; Chou, TY; Coudry, R; Raskin, GA; Fox, SB; Huang, CC; Jeon, YK; Ko, YH; Ku, WH; Kwon, GY; Leslie, C; Lin, MC; Lou, PJ; Scapulatempo-Neto, C; Mendoza Ramirez, S; Savelov, N; Shim, HS; Lara Torres, CO; Cunha, IW; Zavalishina, L; Chen, YM;
Details: Publication Year 2023-02,Volume 55,Issue #1,Page 19-30
Journal Title: Pathology
Publication Type: Research article
Abstract: PD-L1 immunohistochemistry has been approved as a diagnostic assay for immunotherapy. However, an international comparison across multiple cancers is lacking. This study aimed to assess the performance of PD-L1 diagnostic assays in non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC) and urothelial cancer (UC). The excisional specimens of NSCLC, HNSCC and UC were assayed by Ventana SP263 and scored at three sites in each country, including Australia, Brazil, Korea, Mexico, Russia and Taiwan. All slides were rotated to two other sites for interobserver scoring. The same cohort of NSCLC was assessed with Dako 22C3 pharmDx PD-L1 for comparison. The PD-L1 immunopositivity was scored according to the approved PD-L1 scoring algorithms which were the percentage of PD-L1-expressing tumour cell (TC) and tumour proportion score (TPS) by Ventana SP263 and Dako 22C3 staining, respectively. In NSCLC, the comparison demonstrated the comparability of the SP263 and 22C3 assays (cut-off of 1%, kappa=0.71; 25%, kappa=0.75; 50%, kappa=0.81). The interobserver comparisons showed moderate to almost perfect agreement for SP263 in TC staining at 25% cut-off (NSCLC, kappa=0.72 to 0.86; HNSCC, kappa=0.60 to 0.82; UC, kappa=0.68 to 0.91) and at 50% cut-off for NSCLC (kappa=0.64 to 0.90). Regarding the immune cell (IC) scoring in UC, there was a lower correlation (concordance correlation coefficient=0.10 to 0.68) and poor to substantial agreements at the 1%, 5%, 10% and 25% cut-offs (kappa= -0.04 to 0.76). The interchangeability of SP263 and 22C3 in NSCLC might be acceptable, especially at the 50% cut-off. In HNSCC, the performance of SP263 is comparable across five countries. In UC, there was low concordance of IC staining, which may affect treatment decisions. Overall, the study showed the reliability and reproducibility of SP263 in NSCLC, HNSCC and UC.
Publisher: Elsevier
Keywords: Humans; *Carcinoma, Non-Small-Cell Lung/diagnosis/pathology; Squamous Cell Carcinoma of Head and Neck/diagnosis; Reproducibility of Results; *Lung Neoplasms/diagnosis/pathology; B7-H1 Antigen; Immunohistochemistry; *Urinary Bladder Neoplasms/pathology; *Carcinoma, Transitional Cell; *Head and Neck Neoplasms/diagnosis; *Neoplasms, Squamous Cell; Biomarkers, Tumor; 22c3; Sp263; interchangeability; reliability; reproducibility
Department(s): Pathology; Laboratory Research
PubMed ID: 36319485
Publisher's Version: https://doi.org/10.1016/j.pathol.2022.07.016
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-06-15 07:25:00

Last Modified: 2023-06-15 07:25:48